<%@ Page Title="" Language="C#" MasterPageFile="~/masterpages/module.master" AutoEventWireup="true" CodeFile="references.aspx.cs" Inherits="secure_modules_module4_references" %>

<asp:Content ID="Content1" ContentPlaceHolderID="contentBreadcrumb" Runat="Server">
    Leczenie \ Referencje
</asp:Content>
<asp:Content ID="Content2" ContentPlaceHolderID="contentSideBar" Runat="Server">
</asp:Content>
<asp:Content ID="Content3" ContentPlaceHolderID="contentMain" Runat="Server">
    <div class="module4page">
        <h1>
            Referencje</h1>
             <div class="icon_reading">
        <ul class="references">
             <li><span>Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis.  
                 <i>Neurology </i>2004; 63 (11 Suppl 5): S12−8.</span></li>
             <li><span>Berger JR. Functional improvement and symptom management in multiple sclerosis: Clinical efficacy of current therapies.  
                 <i>Am J Manag Care</i> 2011; 17 Suppl 5: S146−53.</span></li>
             <li><span>Zwibel HL, Smrtka J.  Improving quality of life in multiple sclerosis: An unmet need.  
                 <i>Am J Manag Care</i> 2011; 17 Suppl 5: S139−45.</span></li>


            <li><span> Kalincik T, Buzzard K, Jokubaitis V, et al. Risk of relapse phenotype recurrence in multiple sclerosis. <i>Mult Scler</i> 2014; 20(11):1511-22.</span></li> 
 <li><span> NHS England. Clinical commissioning policy: Disease Modifying Therapies for Patients with multiple sclerosis. May 2014. <a href="http://www.england.nhs.uk/wp-content/uploads/2013/10/d04-p-b.pdf" target="_blank">http://www.england.nhs.uk/wp-content/uploads/2013/10/d04-p-b.pdf</a></span></li>





             <li><span>Sellebjerg F, Barnes D, Filippini G, <i>et al</i>. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. 
                 <i>Eur J Neurol</i> 2005; 12(12): 939–46.</span></li>
             <li><span>Potagas C, Mitsonis C, Watier L, <i>et al</i>. Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study.<i> Mult Scler</i> 2008; 14(9): 1262–8.</span></li>


           <li><span> Matheson B, Porter F. The evolution of a relapse clinic for multiple sclerosis: challenges and recommendations. <i>Br J of Nursing</i> 2006; 2 (4):180–186.</span></li>
<li><span> Liu C, Blumhardt LD.<a href="http://www.ncbi.nlm.nih.gov/pubmed/10096099" target="_blank"> Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better?</a> Mult Scler 1999; 5(1):22–8.</span></li>
<li><span> Ross AP, Halper J, Harris CJ. Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective. <i>Int J MS Care</i> 2012; 14(3):148–159.</span></li>



          <%--  11--%>

<li><span> Tremlett H, Zhao Y, Joseph J, Devonshire V. Relapses in multiple sclerosis are age- and time-dependent. <i>J Neurol Neurosurg Psychiatry</i> 2008; 79(12):1368–1374.</span></li>


             <li><span>Confavreux C and Vukusic S. The natural history of multiple sclerosis.<i> Rev Prat </i>2006; 56(12): 1313−20.</span></li>
             <li><span>Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. 
                 <i>J Neurol Neurosurg Psychiatry</i> 1998; 65(3): 362−5.</span></li>
             <li><span>Burton JM, O'Connor PW, Hohol M, <i>et al</i>. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. 
                 <i>Cochrane Database Syst Rev</i> 2009; (3): CD006921.</span></li>
             <li><span>NICE 2003. Management of multiple sclerosis in primary and secondary care. Clinical Guideline 8.</span></li>

           <li><span>National Institute of Clinical Excellence UK. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. October 2014. <a href="http://www.nice.org.uk/guidance/cg186" target="_blank">http://www.nice.org.uk/guidance/cg186</a></span></li>
<li><span> Kopke S, Kasper J, Muhlhauser I, Nubling M, Heesen C. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. <i>Mult Scler 2009</i>; 15(1):96-104.</span></li>

             <li><span>Sellebjerg F, Christiansen M, Jensen J, <i>et al</i>. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. 
                 <i>Eur J Neurol</i> 2000; 7(3): 281−9.</span></li>
             <li><span> Sellebjerg F, Nielsen HS, Frederiksen JL, <i>et al</i>. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. 
                 <i>Neurology </i>1999; 52(7): 1479−84.</span></li>
             <li><span>Beck RW and Cleary PA. Optic neuritis treatment trial: One-year follow-up results.<i> Arch Ophthalmol</i> 1993; 111(6): 773−5.</span></li>


         <%--   21--%>
             <li><span>Cleary PA, Beck RW, Bourque LB, <i>et al</i>. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. 
                 <i>J Neuroophthalmol </i>1997; 17(1): 18−23.</span></li>
             <li><span>Craig J, Young CA, Ennis M, et al. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosispatients receiving intravenous steroid treatment. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 2003; 74 (9): 1225−30.</span></li>
             <li><span>Burgess M. Improving relapse management in multiple sclerosis: a nurse-led model. 
                 <i>Br J Neurosci Nurs</i> 2011; 7: 441–4.</span></li>
             <li><span>Kanis JA, Johansson H, Oden A, <i>et al</i>. A meta-analysis of prior corticosteroid use and fracture risk.<i> J Bone Miner Res</i> 2004; 19(6): 893–9.</span></li>


  <li><span> Nickerson M, Marrie R A. <a href="http://www.msdiscovery.org/papers/biblio/7528-multiple-sclerosis-relapse-experience-patient-reported-outcomes-north-american" target="_blank">The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.</a>. <i>BMC Neurol</i> 2013; 13(1):119.</span></li> 
 <li><span> Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21242498" target="_blank">Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</a>. <i>Neurology 2011</i>; 76(3):294–300.</span></li>
 <li><span> Morrow SA, McEwan L, Alikhani K, Hyson C, Kremenchutzky M. MS patients report excellent compliance with oral prednisone for acute relapses. <i>Can J Neurol Sci</i> 2012; 39(3):352–4.</span></li>
 <li><span> Multiple Sclerosis Nurse Specialist Consensus Committee (1998) Multiple Sclerosis: Best Practices in Nursing Care, New York NY MSNCC</span></li>
 <li><span> Warner, R; Thomas, D and Martin, R (2005) Improving service delivery for relapse management in multiple sclerosis. <i>British Journal of Nursing</i> 2005; 14 (14): 746–753.</span></li>
 <li><span> Hanson KA, Agashivala N, Wyrwich KW, et al.<a href="http://www.msdiscovery.org/papers/biblio/10562-treatment-selection-and-experience-multiple-sclerosis-survey-neurologists" target="_blank"> Treatment selection and experience in multiple sclerosis: survey of neurologists.</a> <i>Patient Prefer Adherence</i> 2014; 8:415–22.</span></li> 







             <li><span>Kappos L, Polman CH, Freedman MS, <i>et al</i>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16914693" target="_blank">Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. </a>
                 <i>Neurology </i>2006; 67(7): 1242−9.</span></li> 
             <li><span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Comi%20G%22[Author]" target="_blank">Comi G</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Martinelli%20V%22[Author]" target="_blank">Martinelli V</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rodegher%20M%22[Author]" target="_blank">Rodegher M</a>, <i>et al</i>. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. 
                 <i>Lancet</i> 2009; 374(9700): 1503−11.</span></li>
             <li><span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lebrun%20C%22[Author]" target="_blank">Lebrun C</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Vermersch%20P%22[Author]" target="_blank"> Vermersch P</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Brassat%20D%22[Author]" target="_blank"> Brassat D</a>, <i>et al</i>. Cancer and multiple sclerosis in the era of disease-modifying treatments. 
                 <i><a href="http://www.ncbi.nlm.nih.gov/pubmed/21293872" target="_blank">J Neurol</a> 2011</i>; 258(7): 1304−11. </span></li>
             <li><span>Gilenya SmPC. <a href="http://www.medicines.org.uk/EMC/medicine/24443/SPC/Gilenya+0.5mg+hard+capsules/" target="_blank">http://www.medicines.org.uk/EMC/medicine/24443/SPC/Gilenya+0.5mg+hard+capsules</a> (accessed 23rd January 2012).</span></li>
             <li><span>Tysabri SmPC. <a href="http://www.medicines.org.uk/EMC/medicine/18447/SPC/TYSABRI+300+mg+concentrate+for+solution+for+infusion /" target="_blank">http://www.medicines.org.uk/EMC/medicine/18447/SPC/TYSABRI+300+mg+concentrate+for+solution+for+infusion</a> (Accessed Jan 23rd, 2012).</span></li>
            <li><span>Bergvall N, Lahoz R, Reynolds T, Korn JR.<a href="http://www.msdiscovery.org/papers/biblio/10736-healthcare-resource-use-and-relapses-fingolimod-versus-natalizumab-treating" target="_blank"> Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.</a> Curr Med Res Opin 2014; 30(8):1461–71.</span></li>

             <li><span>Dhib-Jalbut S. Mechanisms of interferon beta action in multiple sclerosis. 
                 <i>Mult Scler </i>1997; 3(6): 397–401.</span></li>
             <li><span>Duda PW, Schmied MC, Cook SL, <i>et al</i>. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. 
                 <i>J Clin Invest</i> 2000; 105(7): 967–76.</span></li>
             <li><span>Matloubian M, Lo CG, Cinamon G,<i> et al</i>. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. 
                 <i>Nature</i> 2004; 427(6972): 355–60. </span></li>
             <li><span>Spiegel S and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. 
                 <i>Nat Rev Mol Cell Biol</i> 2003; 4(5): 397–407. </span></li>


         <%--   41--%>
             <li><span>Brinkmann V, Davis MD, Heise CE, <i>et al</i>. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. 
                 <i>J Biol Chem </i>2002; 277(24): 21453–7. </span></li>
             <li><span>Gräler MH and Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. 
                 <i>FASEB J</i> 2004; 18(3): 551–3. </span></li>
             <li><span>Schwab SR, Pereira JP, Matloubian M, <i>et al</i>. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients.<i> Science</i> 2005; 309(5741): 1735–9. </span></li>
             <li><span>Wei SH, Rosen H, Matheu MP, <i>et al</i>. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. 
                 <i>Nat Immunol</i> 2005; 6(12): 1228–35.</span></li>
             <li><span>Steinman L. Blocking adhesion molecules as therapy for MS: Natalizumab. 
                 <i>Nat Rev Drug Discov</i> 2005; 4(6); 510−8.</span></li>
             <li><span>Fox EJ. Mechanism of action of mitoxantrone. <i>Neurology</i> 2004; 63(12 Suppl 6): S15–8</span></li>

            <li><span>Warnke C, Meyere zu Hörste G, Hartung HP, <i>et al</i>.<a href="http://www.ncbi.nlm.nih.gov/pubmed/19557143" target="_blank">Review of teriflunomide and its potential in the treatment of multiple sclerosis.</a> <i>Neuropsychiatr Dis Treat </i>2009; 5: 333−40.</span></li>

             <li><span>Linker R and Kieseier BC. Innovative monoclonal antibodies therapies in multiple sclerosis.<i> Ther Adv Neurol Disord</i> 2008; 1(1): 43–52.</span></li>
            <li><span>Ockenfels HM, Schultewolter T, Ockenfels G, <i>et al</i>. The antips	oriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. <i>Br J Dermatol </i>1998; 139(3): 390–5.</span></li>


             <%--<li><span>Wegner C, Pfortner R, Bruck W. Laquinimod rescue therapy in mice with experimental autoimmune encephalomyelitis. 
                 <i>Mult Scler</i> 2010; 16: S41–196. Abstract P251.</span></li>
             <li><span>Ockenfels HM, Schultewolter T, Ockenfels G, <i>et al</i>. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. 
                 <i>Br J Dermatol</i> 1998; 139(3): 390–5.</span></li>--%>


             <li><span>Chen XL, Dodd G, Thomas S, <i>et al</i>. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. 
                 <i>Am J Physiol Heart Circ Physiol </i>2006; 290(5): H1862–70.</span></li>

           <%-- 51--%>
             <li><span>Itoh K, Chiba T, Takahashi S, <i>et al</i>. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. 
                 <i>Biochem Biophys Res Commun</i> 1997; 236(2): 313–22.</span></li>
             <li><span>Venugopal R and Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. 
                 <i>Oncogene </i>1998; 17(24): 3145–56.</span></li>
             <li><span>Loewe R, Pillinger M, de Martin R, <i>et al</i>. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
                 <i>J Invest Dermatol</i> 2001; 117(6): 1363–8.</span></li>
             <li><span>Wegner C, Pfortner R, Bruck W. Laquinimod rescue therapy in mice with experimental autoimmune encephalomyelitis. <i>Mult Scler</i> 2010; 16: S41–196. Abstract P251.</span></li>
             <li><span>Wong J, Gomes T, Mamdani M, <i>et al</i>. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
                 <i>Can J Neurol Sci</i> 2011; 38(3): 429–33.</span></li>
             <li><span>Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in MS: initial validation and association with self-report. 
                 <i>Mult Scler </i>2010; 16(1): 112–20.</span></li>
             <li><span>Kendrew P, Ward F, Buick D,<i> et al</i>. Satisfaction with information and its relationship with adherence in patients with chronic pain. 
                 <i>Int J Pharm Pract </i>2001; 9(Suppl): 5.</span></li>
             <li><span>Ross AP. Tolerability, adherence, and patient outcomes.<i> Neurology </i>2008; 71(24 Suppl 3): S21−3. <a href="https://login.medscape.com/login/sso/getlogin?urlCache=aHR0cDovL3d3dy5tZWRzY2FwZS5vcmcvbWVkbGluZS9hYnN0cmFjdC8xOTA2NDg3MQ==&ac=401" target="_blank">Abstract</a></span></li>
             <li><span>Elwyn G, Edwards A, Britten N. ‘Doing Prescribing’: how clinicians work differently for better, safer care. 
                 <i>Qual Saf Health Care</i> 2003; 12 Suppl 1: i33–6</span></li>
             <li><span>Munschauer FE and Weinstock-Guttman B (2005) Importance of adherence to and persistence with prescribed treatments in patients with Multiple Sclerosis. 
                 Available: <a href="http://www.touchneurology.com/importance-adherence-persistence-with-a1879-1.html." target="_blank">www.touchneurology.com/importance-adherence-persistence-with-a1879-1.html</a>.</span></li>

       <%--     61--%>
             <li><span>Burgess M. The use of interferon beta-1b (Betaferon) in multiple sclerosis and the MS nurses’ role. 
                 <i>Bri J Neurosci Nurs</i> 2005; 1(3): 132–8</span></li>
            <li><span><a href="http://www.rebismart.com/en/patient_services/patient_services.html" target="_blank">http://www.rebismart.com/en/patient_services/patient_services.html</a></span></li>
            <li><span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Willis%20H[Author]&cauthor=true&cauthor_uid=24966669" target="_blank">Willis H</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Webster%20J[Author]&cauthor=true&cauthor_uid=24966669" target="_blank"> Webster J</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Larkin%20AM[Author]&cauthor=true&cauthor_uid=24966669" target="_blank">Larkin AM</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Parkes%20L[Author]&cauthor=true&cauthor_uid=24966669" target="_blank"> Parkes L</a>. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device. Patient Prefer Adherence 2014; 8: 843–51.</span></li>
                
             <li><span>Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence long term. 
                 <i>Medscape J Med.</i> 2008;10:225. Available at: <a href="http://www.medscape.com/viewarticle/579961" target="_blank">http://www.medscape.com/viewarticle/579961</a></span></li>
             <li><span>Brandes DW, Callender T, Lathi E, <i>et al</i>. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. 
                 <i>Curr Med Res Opin</i> 2009; 25(1): 77−92.</span></li>
             <li><span>Cramer JA, Cuffel BJ, Divan V, <i>et al</i>. Patient satisfaction with an injection device for multiple sclerosis treatment. 
                 <i>Acta Neurol Scand</i> 2006; 113(3): 156−62.</span></li>
             <li><span>Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. 
                 <i>Neurology</i> 2004; 63(11 Suppl 5): S35−41.</span></li>

            <li><span>Filipi M, Beavin J, Brillante R, <i>et al</i>. Nurses’ Perspective on Approaches to Limit Flu-Like Symptoms during Interferon Therapy for Multiple Sclerosis. <i>Int J MS Care</i> 2014; 16: 55–60.</span></li>
            <li><span>Remington G, Rodriguez Y, Logan D, <i>et al</i>. Facilitating Medication Adherence in Patients with Multiple Sclerosis.<i> Int J MS Care </i>2013; 15(1): 36–45.</span></li>
            <li><span>Calabresi P, Kieisier B, Arnold D,<i> et al</i>. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.<i> Lancet Neurol </i>2014; 13 (7): 657–665.</span></li>



         <%--    <li><span>Matson MA, Zimmerman TR Jr, Tuccillo D, <i>et al</i>. Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation. 
                 <i>Curr Med Res Opin</i> 2011; 27(12): 2271−8. </span></li>--%>
             <li><span>Galetta SL, Markowitz C, Lee AG. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12390057" target="_blank">Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.</a> 
                 <i>Arch Int Med</i> 2002; 162(19); 2161−9.</span></li>

          <%--  71--%>
             <li><span>Durelli L, Verdun E, Barbero P, <i>et al</i>.<a href="http://www.ncbi.nlm.nih.gov/pubmed/11988242" target="_blank"> Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)</a>. 
                 <i>Lancet </i>2002; 359(9316):1453−60. </span></li>
             <li><span>Schwald SR, Panitch HS. Full results of the Evidence of Interferon Dose-response-European North American Comparative Efficacy (EVIDENCE) study: a multicentre, randomised, assessor-blinded comparison of low dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. 
                 <i>Clin Ther</i> 2007; 29(9): 2031−48</span></li>
             <li><span>O'Connor P, Filippi M, Arnason B, <i>et al</i>. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. 
                 <i>Lancet Neurol </i>2009; 8(10): 889−97. </span></li>
             <li><span>Mikol DD, Berkhof F, Cheng P,<i> et al</i>. REGARD Study Group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing remitting multiple sclerosis; a multicentre, randomised, parrallel, open-label trial.<i> Lancet Neurol</i> 2008; 7(10): 903−14.</span></li>
             <li><span>Brochet B, Lemaire G, Beddiaf A.  et l’Epicure Study Group.<a href="http://www.ncbi.nlm.nih.gov/pubmed/16840982" target="_blank"> Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices</a>. 
                 <i>Rev Neurol (Paris) </i>2006; 162(6–7): 735–40.</span></li>
             <li><span>Kozubski W. Autoinjector improves injection-related tolerability issues in patients with multiple sclerosis – exploring the new ExtavijectTM 30G system for the injection of interferon beta-1b. 
                 <i>Eur Neurol Rev</i> 2010; 5(2): 77–81</span></li>
             <li><span>Ebers G<i> et al</i>. Presented at 58th American Academy of Neurology Annual Meeting; April 2006; San Diego, CA.</span></li>
             <li><span>Goodin DS <i>et al</i>. Presented at 131st ANA Annual Meeting, October 2006; Chicago, IL. </span></li>
             <li><span>Kappos L, Freedman MS, Polman CH, <i>et al</i>.<a href="http://www.ncbi.nlm.nih.gov/pubmed/17679016" target="_blank"> Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.</a> Lancet 2007; 370(9585): 389−97.</span></li>
             <li><span>Betaferon SmPC. <a href="http://www.medicines.org.uk/EMC/medicine/1809/SPC/Betaferon" target="_blank">http://www.medicines.org.uk/EMC/medicine/1809/SPC/Betaferon</a> (Date accessed January 25<sup>th</sup>, 2012).</span></li>

       <%--     81--%>
             <li><span>Extavia SmPC. <a href="http://www.medicines.org.uk/EMC/medicine/21659/SPC/Extavia" target="_blank">http://www.medicines.org.uk/EMC/medicine/21659/SPC/Extavia/</a> (Date accessed January 25<sup>th</sup>, 2012).</span></li>
             <li><span>Andersen O, Elovaara I, Färkkilä M, <i>et al</i>.  Multicentre, randomised, double blind, placebo controlled phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.  
                 <i>J Neurol Neurosurg Psychiatry</i> 2004; 75(5): 706−10.</span></li>
             <li><span>Avonex SmPC.<a href="http://www.medicines.org.uk/emc/medicine/17516" target="_blank">http://www.medicines.org.uk/emc/medicine/17516</a> </span></li>
             <li><span>Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. 
                 <i>CNS Drugs</i> 2009; 23(5): 379−96.</span></li>

             <li><span>van Beers MM, Jiskoot W, Schellekens H. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. 
                 <i>J Interferon Cytokine Res</i> 2010; 30(10): 767−75.</span></li>
            <li><span>Fox E, Green B, Markowitz C, <i>et al.</i>  The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis. <i>BMC Neurology </i>2014; 14:73</span></li>
            <li><span>Lublin F, Cofield S, Cutter G, <i>et al</i>. Randomized study comparing interferon and glatiramer acetate in multiple sclerosis. <i>Ann Neurol </i>2013; 73(3): 327–40.</span></li>


             <li><span>Copaxone SmPC.</span></li>
             <li><span>Edgar CM, Brunet DG, Fenton P, <i>et al</i>.<a href="http://www.ncbi.nlm.nih.gov/pubmed/15038472" target="_blank"> Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.</a> 
                 <i>Can J Neurol Sci </i>2004; 31(1): 58−63.</span></li>

             <li><span>Chun J and Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. 
                 <i>Clin Neuropharmacol</i> 2010; 33(2): 91–101.</span></li>

         <%--   91--%>
             <li><span>Aktas O, Küry P, Kieseier B, <i>et al</i>.<a href="http://www.ncbi.nlm.nih.gov/pubmed/20551946" target="_blank">Fingolimod is a potential novel therapy for multiple sclerosis. </a> 
                 <i>Nat Rev Neurol </i>2010; 6(7): 373−82.</span></li>
             <li><span>Mehling M, Lindberg R, Raulf F, <i>et al</i>.<a href="http://www.ncbi.nlm.nih.gov/pubmed/20592255" target="_blank"> Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.</a>
                 <i>Neurology</i> 2010; 75(5): 403−10. </span></li>
             <li><span>Kappos L, Radue EW, O'Connor P, <i>et al</i>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20089952" target="_blank">A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. </a>
                 <i>N Engl J Med</i> 2010; 362(5): 387–401.</span></li>
             <li><span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cohen%20JA%22[Author]" target="_blank">Cohen JA</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Barkhof%20F%22[Author]" target="_blank"> Barkhof F</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Comi%20G%22[Author]" target="_blank">Comi G</a>, <i>et al</i>. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
                 <i>N Engl J Med</i> 2010; 362(5): 402–15.</span></li>
             <li><span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Khatri%20B%22[Author]" target="_blank">Khatri B</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Barkhof%20F%22[Author]" target="_blank">Barkhof F</a>,<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Comi%20G%22[Author]" target="_blank">Comi G</a> , <i>et al</i>. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. 
                 <i>Lancet Neurol </i>2011; 10(6): 520–9.</span></li>
             <li><span>Khatri BO, Man S, Giovannoni G, <i>et al</i>. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. <i>Neurology</i> 2009; 72(5): 402−9.</span></li>
             <li><span>Polman CH, O'Connor PW, Havrdova E,<i> et al</i>. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. 
                 <i>N Engl J Med</i> 2006; 354(9): 899−910.</span></li>
             <li><span>Bloomgren G, Richman S, Hotermans C,<i> et al</i>. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.  
                 <i>N Engl J Med</i> 2012; 366(20): 1870−80.</span></li>
            <li><span>Ward-Abel N, Vernon K, Warner R. An exciting era of treatments for relapsing-remitting multiple sclerosis. <i>Br J Neuroscience Nursing </i>2014; 10 (1): 21–28.</span></li>
            <li><span>Fox R, Cree B, De Seze J, <i>et al</i>. MS disease activity in RESTORE: A randomized, 24-week natalizumab treatment interruption study.<i> Neurology</i> 2014; 82(17): 1491–1498.</span></li>

          <%--  101--%> 
             <li><span>Hartung HP, Gonsette R, König N, <i>et al</i>. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicentre trial. 
                 <i>Lancet</i> 2002; 360(9350): 2018–25.</span></li>
             <li><span>Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. 
                 <i>Clin Ther </i>2006; 28(4): 461−74.</span></li>
             <li><span>Mitoxantrone SmPC. <a href="http://www.medicines.org.uk/EMC/medicine/10050/SPC/Mitoxantrone+(Mitozantrone)+2+mg+ml+Sterile+Concentrate" target="_blank">
                 http://www.medicines.org.uk/EMC/medicine/10050/SPC/Mitoxantrone+(Mitozantrone)+2+mg+ml+Sterile+Concentrate </a> (accessed 23rd January 2012).</span></li>
             <li><span>Novantrone US prescribing information.<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf (Accessed 23rd January 2012).</a></span></li>
             <li><span>LePage E, Leray E, Edan G; French Mitoxantrone Safety Group. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.  
                 <i>Mult Scler</i> 2011; 17(7): 867−75.</span></li>
            <li><span>O’Connor P, Wolinsky J, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.  <i>N Engl J Med </i>2011; 365:1293–1303.</span></li>

            <li><span>Confavreux C, O'Connor P, Comi G, Vermersch<i> et al</i>. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.<i> Lancet Neurol </i>2014; 13(3):247–56. </span></li>
            <li><span>Vermersch P, Czlonkowska A, Grimaldi L,<i> et al</i>. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <i>Mult Scler </i>2014; 20(6): 705-16.</span></li>


             <li><span>Miller A, Wolinsky J, Kappos L, <i>et al</i>.  Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.<i> Lancet Neurol </i>2014; 13(10):977–86.</span></li>
            <li><span>Gold R, Kappos L, Arnold D, <i>et al</i>. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.<i> N Engl J Med</i> 2012; 367:1098–107.</span></li>

          <%--  111--%>

            <li><span>Fox RJ, Miller DH, Phillips JT, <i>et al</i>. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>N Engl J Med </i>2012; 367: 1087–97.</span></li>
            <li><span>Hutchinson M, Fox R, Havrodova E, <i>et al</i>. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.<i> Curr Med Res Opin</i> 2014; 30(4):613–27. </span></li>

            <li><span>FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate).<a href=" http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm" target="_blank"> http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm</a></span></li>
            <li><span>Dimethyl fumarate SmPC <a href="http://www.medicines.org.uk/emc/medicine/28593/SPC/Tecfidera+120mg+gastro-resistant+hard+capsules/" target="_blank">http://www.medicines.org.uk/emc/medicine/28593/SPC/Tecfidera+120mg+gastro-resistant+hard+capsules/ </a></span></li>
            <li><span>Cohen J, Coles A, Arnold D, <i>et al</i>. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.<i> Lancet </i>2012; 380(9856): 1819–28.</span></li>


            <li><span>Coles A, Twyman C, Arnold D, <i>et al</i>. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.<i> Lancet</i> 2012; 380 (9856): 1829–39.</span></li>

            <li><span>Krieger S, <i>et al</i>. Alemtuzumab is efficacious in highly-active RRMS patients in CARE-MS II. <i>CMSC-ACTRIMS 2013; Abstract DX01</i>.</span></li>
            <li><span>Caon C, Meyer C, Mayer L, Shelton Smith M. Efficacy and Safety of Alemtuzumab in Multiple Sclerosis and Impact on Nursing Role.<i> Int J MS Care 2013;</i> 15(4): 159–168.</span></li>

             <li><span>Nicholas R, Giannetti P, Alsanousi A, <i>et al</i>. Development of oral immunomodulatory agents in the management of multiple sclerosis. 
                 <i>Drug Des Devel Ther </i>2011; 5: 255−74.</span></li>
             <li><span>Barten LJ, Allington DR, Procacci KA, <i>et al</i>. New approaches in the management of multiple sclerosis. 
                 <i>Drug Des Devel Ther </i>2010; 4: 343−66.</span></li>


           <%-- 121--%>
             <li><span>Baum HM, Rothschild BB. Multiple sclerosis and mobility restriction. <i>Arch Phys Med Rehabil</i> 1983; 64(12): 591–6.</span></li>
             <li><span>Hayes KC. Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. 
                 <i>Neuropsychiatr Dis Treat</i> 2011; 7: 229–39.</span></li>
             <li><span>Salter AR, Cutter GR, Tyry T, et al. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. 
                 <i>Curr Med Res Opin</i> 2010; 26(2): 493–500.</span></li>
             <li><span>Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. 
                 <i>Adv Ther </i>2009; 28(12): 1043−57.</span></li>
             <li><span>Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. 
                 <i><a href="http://informahealthcare.com/loi/erp" target="_blank">Expert Rev Pharmacoecon Outcomes Res </a></i> 2010; 10(4): 433−40.</span></li>
             <li><span>Souza A, Kelleher A, Cooper R, <i>et al</i>. Multiple sclerosis and mobility-related technology: sytematic review of literature. 
                 <i>J Rehabil Res Dev </i>2010; 47(3): 213–23.</span></li>
             <li><span>Goodman AD, Brown TR, Edwards KR, <i>et al</i>. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. 
                 <i>Ann Neurol </i>2010; 68(4): 494–502.</span></li>
             <li><span>Goodman AD, Brown TR, Krupp LB,<i> et al.</i> Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. 
                 <i>Lancet</i> 2009; 373(9665): 732−8.</span></li>
             <li><span>Fampyra SmPC <a href="http://www.medicines.org.uk/EMC/medicine/25003/SPC/Fampyra+10+mg+prolonged-release+tablets/" target="_blank">http://www.medicines.org.uk/EMC/medicine/25003/SPC/Fampyra+10+mg+prolonged-release+tablets/</a> - Accessed January 14<sup>th</sup>, 2012).</span></li>
            <%-- <li><span>Hayes KC. Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. 
                 <i>Neuropsychiatr Dis Treat</i> 2011; 7: 229-39.</span></li>--%>
            <li><span>Hayes 2012</span></li>
             <li><span>Judge SI and Bever CT Jr. Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. 
                 <i>Pharmacol Ther</i> 2006; 111(1): 224–59.</span></li>
             <li><span>Brar SP, Smith MB, Nelson LM, <i>et al</i>. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis.  
                 <i>Arch Phys Med Rehabil </i>1991; 72(3): 186−9.</span></li>

          <%--  131--%>
             <li><span>Schapiro RT and Langer SL. Symptomatic therapy of multiple sclerosis.<i> Curr Opin Neurol
                 </i>1994; 7(3): 229−33.</span></li>
             <li><span>Baclofen SmPC.<a href="https://www.medicines.org.uk/emc/medicine/23850" target="_blank">https://www.medicines.org.uk/emc/medicine/23850</a></span></li>
             <li><span>Tizanidine SmPC. Actavis Pharma <a href="http://www.medicines.org.uk/EMC/medicine/24095/SPC/Tizanidine+2mg+Tablets " target="_blank">http://www.medicines.org.uk/EMC/medicine/24095/SPC/Tizanidine+2mg+Tablets</a> – Date accessed January 14th, 2012.</span></li>
             <li><span>Paisley S, Beard S, Hunn A,<i> et al</i>. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. 
                 <i>Mult Scler </i>2002; 8(4): 319−29.</span></li>
             <li><span>Novotna A, Mares J, Ratcliffe S, <i>et al</i>. A randomized, double blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®) as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. 
                 <i>Eur J Neurol</i> 2011; 18(9): 1122−31.</span></li>
             <li><span>Collin C, Ehler E, Waberzinek G, <i>et al</i>. A double-blind randomized placebo-controlled parallel-group study of Sativex in subjects with symptoms of spasticity due to multiple sclerosis. 
                 <i>Neurol Res</i> 2010; 32(5): 451−9.</span></li>
             <li><span>Edgely K, Sullivan M, Deboux E.  A survey of multiple sclerosis: part 2.  Determinants of employment status.<i>  Can J Rehab</i> 1991; 4: 127−32.</span></li>
             <li><span>Amato MP, Portaccio E. Management options in multiple sclerosis-associated fatigue.<i> Expert Opin Pharmacother</i> 2012; 13(2): 207−16.</span></li>
             <li><span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tsang%20BK%22[Author]" target="_blank">Tsang BK</a> and<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Macdonell%20R%22[Author]" target="_blank"> Macdonell R</a>. Multiple sclerosis - diagnosis, management and prognosis. 
                <i>Aust Fam Physician</i> 2011; 40(12): 948−55.</span></li>
             <li><span>Krupp LB, Coyle PK, Doscher C, <i>et al</i>. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
                 <i>Neurology </i>1995; 45(11): 1956−61.</span></li>


          <%--  141--%>
             <li><span>Zifko UA, Rupp M, Schwarz S, <i>et al</i>. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.<i> J Neurol</i> 2002; 249(8): 983−7.</span></li>
             <li><span>Rammohan KW, Rosenberg JH, Lynn DJ, <i>et al</i>. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. 
                 <i>J Neurol Neurosurg Psychiatry</i> 2002; 72(2): 179−83.</span></li>
             <li><span>Lange R, Volkmer M, Heesen C, <i>et al</i>. Modafinil effects in multiple sclerosis patients with fatigue.
                 <i>J Neurol</i> 2009; 256(4): 645−50.</span></li>
             <li><span>Stankoff B, Waubant E, Confavreux C, <i>et al</i>. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. 
                 <i>Neurology</i> 2005; 64(7): 1139−43.</span></li>
             <li><span>Möller F, Poettgen J, Broemel F, <i>et al</i>. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double blind study with modafinil for treatment of fatigue in patients with multiple sclerosis.<i> Mult Scler</i> 2011; 17(8): 1002−9.</span></li>
             <li><span>Foster HE Jr. Bladder symptoms and multiple sclerosis. <i>MSQR</i> 2002; 21: Spring.</span></li>
             <li><span>Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. 
                 <i>J Urol</i>. 1999; 161(3): 743−57.</span></li>
             <li><span>Rosenberg MT and Dmochowski RR.  Overactive bladder: Evaluation and management in primary care. 
                 <i>Cleve Clin J Med</i> 2005; 72(2): 149−56.</span></li>


         
             <li><span>Nicholas RS, Friede T, Hollis S, <i>et al</i>. Anticholinergics for urinary symptoms in multiple sclerosis. 
                 <i>Cochrane Database Syst Rev </i>2009; (1): CD004193.</span></li>
             <li><span>Staskin DR and MacDiarmid SA. Using anticholinergics to treat overactive bladder: The issue of treatment tolerability. 
                 <i>Am J Med</i> 2006; 119(3 Suppl 1): 9−15.</span></li>

            <%--   151--%>
             <li><span>MacDiarmid SA, Peters KM, Shobeiri A, <i>et al</i>. long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. 
                 <i>J Urol</i> 2010; 183(1): 234−40.</span></li>
             <li><span>De Sèze M, Raibaut P, Gallien P, <i>et al</i>.  Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study.  
                 <i>Neurourol Urodyn</i> 2011; 30(6): 306−11.</span></li>
             <li><span>Apostolidis A, Dasgupta P, Denys P, <i>et al</i>.  Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunction: A European consensus report.<i>  Eur Urol</i> 2009; 55(1): 100−19.</span></li>
             <li><span>Schulte-Baukloh H, Schobert J, Stolze T, <i>et al</i>. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: An objective and subjective analysis. 
                 <i>Neurourol Urodyn</i> 2006; 25(2): 110−5.</span></li>
             <li><span>Mehnert U, Birzele J, Reuter K, <i>et al</i>.  The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: A pilot study. 
                 <i>J Urol</i>. 2010; 184(3): 1011−6.</span></li>
             <li><span>Deffontaines-Rufin S, Weil M, Verollet D, <i>et al</i>.  Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. 
                 <i>Int Braz J Urol</i> 2011; 37: 642−8.</span></li>
             <li><span>Wiesel PH, Norton C, Glickman S, <i>et al</i>. Pathophysiology and management of bowel dysfunction in multiple sclerosis. 
                 <i>Eur J Gastroenterol Hepatol</i> 2001; 13(4): 441–8.</span></li>
             <li><span>Preziosi G and Emmanuel A. Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. 
                 <i>Expert Rev Gastroenterol Hepatol</i> 2009; 3(4): 417–23.</span></li>
             <li><span>Govaert B, van Gemert WG, Baeten CG. Neuromodulation for functional bowel disorders. 
                 <i>Best Pract Res Clin Gastroenterol</i> 2009; 23(4): 545–53.</span></li>
             <li><span>Tepavcevic DK, Kostic J, Basuroski ID, <i>et al</i>. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis.
                 <i>Mult Scler</i> 2008; 14(8): 1131–36.</span></li>


       <%--     161--%>

             <li><span>Zorzon M, Zivadinov R, Bosco A, <i>et al</i>. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups.
                 <i>Mult Scler</i> 1999; 5(6): 418–27.</span></li>
             <li><span>Betts CD, Jones SJ, Fowler CG, <i>et al</i>. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. 
                 <i>Brain</i> 1994; 117(Pt 6): 1303–10.</span></li>
             <li><span>NCCCC (National Collaborating Centre for Chronic Conditions). Multiple sclerosis; National clinical guideline for diagnosis and management in primary and secondary care. London (UK): National Institute for Clinical Excellence (NICE); 2004. Available at:<a href="http://www.rcplondon.ac.uk/pubs/contents/409ed7a2-ae44-472f-ba3bab7164229493" target="_blank">http://www.rcplondon.ac.uk/pubs/contents/409ed7a2-ae44-472f-ba3bab7164229493 </a> </span></li>
             <li><span>Dachille G, Ludovico GM, Pagliarulo G, <i>et al</i>. Sexual dysfunctions in multiple sclerosis. 
                 <i>Minerva Urol Nefrol</i> 2008; 60(2): 77–9.</span></li>
             <li><span>Lombardi G, Macchiarella A, Del Popolo G. Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. 
                 <i>J Sex Med</i> 2010; 7(6): 2192−200.</span></li>
             <li><span>Shifren JL. The role of androgens in female sexual dysfunction. <i>Mayo Clin Proc</i> 2004; 79(4 Suppl): S19–24.</span></li>
            <li><span>Lúcio AC, D'Ancona CA, Lopes MH, Perissinotto MC, Damasceno BP. The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis. <i>Mult Scler </i>2014; 20(13): 1761–8.</span></li>


             <li><span><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Giordano%20A[Author]&cauthor=true&cauthor_uid=21621796" target="_blank">Giordano A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Granella%20F[Author]&cauthor=true&cauthor_uid=21621796" target="_blank">Granella F</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lugaresi%20A[Author]&cauthor=true&cauthor_uid=21621796" target="_blank">Lugaresi A</a>, <i>et al</i>. Anxiety and depression in multiple sclerosis patients around diagnosis. 
                 <i>J Neurol Sci</i> 2011; 307(1-2): 86-91. </span></li>
             <li><span>Jones KH, Ford DV, Jones PA, John A, <i>et al</i>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22860028" target="_blank">A Large-Scale Study of Anxiety and Depression in People with Multiple Sclerosis: A Survey via the Web Portal of the UK MS Register.</a> 
                 <i>PLoS One </i>2012; 7(7): e41910.  Epub 2012 Jul 30.</span></li>
             <li><span>DeSousa EA, Albert RH, Kalman B. Cognitive impairments in multiple sclerosis: a review. 
                 <i>Am J Alzheimers Dis Other Demen </i>2002; 17(1): 23–9.</span></li>


      <%--      171--%>
             <li><span>Huijbregts SC, Kalkers NF, de Sonneville LM, <i>et al</i>. Cognitive impairment and decline in different MS subtypes. 
                 <i>J Neurol Sci</i> 2006; 245(1–2): 187–94.</span></li>
             <li><span>Krupp LB, Christodoulou C, Melville P,<i> et al</i>. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. 
                 <i>Neurology</i> 2004; 63(9): 1579–85.</span></li>
             <li><span>Villoslada P, Arrondo G, Sepulcre J, <i>et al</i>. Memantine induces reversible neurologic impairment in patients with MS.
                 <i>Neurology </i>2009; 72(19): 1630–3</span></li>
             <li><span>Shaygannejad V, Janghorbani M, Ashtari F, <i>et al</i>. Effects of rivastigmine on memory and cognition in multiple sclerosis.
                 <i>Can J Neurol Sci</i> 2008; 35(4): 476–81.</span></li>
             <li><span>Solaro C, Tanganelli P, Messmer Uccelli M.  Pharmacological treatment of pain in multiple sclerosis. 
                 <i>Expert Rev Neurother</i> 2007; 7(9): 1165−74.</span></li>
             <li><span>Lyrica SmPC.<a href="http://www.medicines.org.uk/EMC/medicine/14651/SPC/Lyrica+Capsules/" target="_blank">http://www.medicines.org.uk/EMC/medicine/14651/SPC/Lyrica+Capsules/</a></span></li>
             <li><span>Pöllmann W and Feneberg W. Current management of pain associated with multiple sclerosis. 
                 <i>CNS Drugs</i> 2008; 22(4): 291−342.</span></li>
             <li><span>Tegretol SmPC. <a href="http://www.medicines.org.uk/EMC/medicine/1328/SPC/Tegretol+Chewtabs+100mg%2c+200mg%2c+Tegretol+Tablets+100mg%2c+200mg%2c+400mg " target="_blank">http://www.medicines.org.uk/EMC/medicine/1328/SPC/Tegretol+Chewtabs+100mg%2c+200mg%2c+Tegretol+Tablets+100mg%2c+200mg%2c+400mg/</a> (Accessed 18-Jan 2012).</span></li>
             <li><span>Keppra SmPC. 
                 <a href="http://www.medicines.org.uk/EMC/medicine/16231/SPC/Keppra+250%2c500%2c750+and+1000+mg+filmcoated+Tablets%2c+100+mg+ml+oral+solution+and+100+mg+ml+concentrate+for+solution+for+infusion/" target="_blank">http://www.medicines.org.uk/EMC/medicine/16231/SPC/Keppra+250%2c500%2c750+and+1000+mg+filmcoated+Tablets%2c+100+mg+ml+oral+<br />solution+and+100+mg+ml+concentrate+for+solution+for+infusion/</a> (Date accessed 18th Jan 2012).</span></li>
             <li><span>Lamictal SmPC.<a href="180. https://www.medicines.org.uk/emc/medicine/4228" target="_blank">https://www.medicines.org.uk/emc/medicine/4228</a></span></li>

          <%--  181--%>
             <li><span>Kassirer M. Multiple Sclerosis and Pain: A Medical Focus. <i>Int J MS Care</i> 2000; 2(3): 30−34.</span></li>
             <li><span>Gidal BE. New and emerging treatment options for neuropathic pain. <i>Am J Manag Care</i> 2006; 12(9 Suppl): S269−78.</span></li>
             <li><span>Yadav V, Shinto L, Bourdette B. Complementary and alternative medicine for the treatment of multiple sclerosis. 
                 <i>Expert Rev Clin Immunol</i> 2010; 6(3): 381–95.</span></li>

            <li><span>Kochs L, Wegener S, Sühnel A, Voigt K, Zettl UK.<a href="http://www.msdiscovery.org/papers/biblio/9903-use-complementary-and-alternative-medicine-patients-multiple-sclerosis" target="_blank"> The use of complementary and alternative medicine in patients with multiple sclerosis: A longitudinal study.</a><i> Complement Ther Med </i>2014; 22 </span></li>
            <li><span>Masullo L, Papas MA, Cotugna N, Baker S, Mahoney L, Trabulsi J. Complementary and Alternative Medicine Use and Nutrient Intake Among Individuals with Multiple Sclerosis in the United States. <i>J Community Health </i>2014 Jul 1. [Epub ahead of print]</span></li>



             <li><span>Linde K, Berner MM, Kriston L. St John's wort for major depression. <i>Cochrane Database Syst Rev</i> 2008; (4): CD000448.</span></li>

            <li><span>Yadav V, Bever C, Bowen J, <i>et al</i>. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.<i> Neurology </i>2014; 82; 1083–1092.</span></li>

            
        </ul>
        </div>
    </div>
</asp:Content>

